Article
Chemistry, Medicinal
Trinh Phuong Vo, Gitika Panicker, Kimberly Braz-Gomes, Ashwin C. Parenky, Ira Rajbhandari, Mangalathu S. Rajeevan, Elizabeth R. Unger, Martin J. D'Souza, Mohammad N. Uddin
Summary: This research developed a microparticulate HPV16 vaccine for transdermal administration and evaluated its immunogenicity in a pre-clinical mouse model. The results showed a significant increase in HPV16 IgG antibodies in the microparticle group and expansion of CD4+, CD45R, CD27 and CD62L cell populations in the vaccinated mice group. This suggests the high efficacy of the microparticulate vaccine when administered via transdermal route.
Review
Immunology
Reeshu Gupta, Kajal Arora, Sourav Singha Roy, Abyson Joseph, Ruchir Rastogi, Nupur Mehrotra Arora, Prabuddha K. Kundu
Summary: Viral infectious diseases pose a threat to human health and global stability. Various vaccine platforms, such as DNA, mRNA, recombinant viral vectors, and virus-like particle-based vaccines, have been developed to combat these diseases. Virus-like particles (VLPs) have shown promise as successful vaccines against prevalent and emerging diseases, but commercialization has been limited so far. Technical difficulties and the need for large-scale production methods have hindered the progress of VLP-based vaccines.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Lauri E. Markowitz, John T. Schiller
Summary: HPV vaccines are highly effective in preventing HPV-attributable cancers and have been introduced into national immunization programs in over 100 countries. The success of these vaccines has sparked interest in ambitious disease reduction goals.
JOURNAL OF INFECTIOUS DISEASES
(2021)
Review
Medical Laboratory Technology
Jill Whitley, Christopher Zwolinski, Christian Denis, Maureen Maughan, Leonie Hayles, David Clarke, Meghan Snare, Hong Liao, Sean Chiou, Tina Marmura, Holly Zoeller, Ben Hudson, John Peart, Monica Johnson, Amelia Karlsson, Yunfei Wang, Cynthia Nagle, Cherell Harris, Daniel Tonkin, Stephanie Fraser, Lieza Capiz, Christina L. Zeno, Yvonne Meli, Diana Martik, Daniel A. Ozaki, Amy Caparoni, Jason E. Dickens, Drew Weissman, Kevin O. Saunders, Barton F. Haynes, Gregory D. Sempowski, Thomas N. Denny, Matthew R. Johnson
Summary: This article introduces an aqueous-based scalable manufacturing process and the accompanying analytical methods for producing mRNA vaccines and therapeutics. It has been shown that this process can be adapted to clinical and commercial scale production, and the resulting products demonstrate good efficacy and protection in animal models. Furthermore, the article discusses the challenges and potential solutions regarding raw material sourcing, supply, and cold chain requirements for mRNA products.
TRANSLATIONAL RESEARCH
(2022)
Review
Multidisciplinary Sciences
Nando Reza Pratama, Ifan Ali Wafa, David Setyo Budi, Manesha Putra, Manggala Pasca Wardhana, Citrawati Dyah Kencono Wungu
Summary: Objective Pregnancy is a known risk factor for severe COVID-19, and it is important to develop safe vaccines for pregnant women. This study reviewed the existing research on COVID-19 vaccination in pregnancy and found that mRNA-based vaccines can prevent SARS-CoV-2 infection without clear harm to pregnancy. The most common adverse reactions were transient and included pain at the injection site, fatigue, and headache. Antibody responses were rapid and strengthened with booster doses. Longer intervals between vaccination and delivery were associated with higher antibody levels in the baby. The study concludes that mRNA vaccines are encouraged for pregnant women, and two doses are recommended for better maternal and fetal antibody responses.
Article
Immunology
Hella Pasmans, Magdalena A. Berkowska, Annieck M. Diks, Bas de Mooij, Rick J. Groenland, Lia de Rond, M. Alina Nicolaie, Sjoerd H. van der Burg, Jacques J. M. van Dongen, Fiona R. M. van der Klis, Anne-Marie Buisman
Summary: A study comparing immune responses in women vaccinated with bivalent and nonavalent HPV vaccines found consistent expansion of plasma cells and monocytes, but varied responses in other immune cells. Antibody levels and memory B and T-cell responses also differed between the two vaccine groups.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Protim Sarker, Evana Akhtar, Rakib Ullah Kuddusi, Mohammed Mamun Alam, Md Ahsanul Haq, Md Biplob Hosen, Bikash Chandra Chanda, Farjana Haque, Muntasir Alam, Abdur Razzaque, Mustafizur Rahman, Faruque Ahmed, Md Golam Kibria, Mohammed Zahirul Islam, Shehlina Ahmed, Rubhana Raqib
Summary: This study investigated the immune response of the Bangladeshi population to four different COVID-19 vaccines. The results showed that mRNA vaccines generated a higher antibody response, while different vaccine types had differential cellular responses.
Article
Virology
D. Scott Schmid, Congrong Miao, Jessica Leung, Michael Johnson, Adriana Weinberg, Myron J. Levin
Summary: The two HZ vaccines, RZV and ZVL, show different humoral responses, with RZV significantly boosting avidity to gE and neutralizing antibodies, providing longer-lasting immune memory.
JOURNAL OF VIROLOGY
(2021)
Review
Biochemistry & Molecular Biology
Magdalini Alexandridi, Julija Mazej, Enrico Palermo, John Hiscott
Summary: Since 2019, Cytokine & Growth Factor Reviews has published multiple Special Issues focusing on the biology, pathogenesis, and therapeutic options for COVID-19. Despite progress in vaccines and treatments, there are challenges posed by misinformation and anti-vaccine sentiment.
CYTOKINE & GROWTH FACTOR REVIEWS
(2022)
Article
Biology
Jessica Swanson, Rennos Fragkoudis, Philippa C. Hawes, Joseph Newman, Alison Burman, Anusha Panjwani, Nicola J. Stonehouse, Tobias J. Tuthill
Summary: This study successfully displayed the N-terminal epitope of FMDV VP4 using HBc VLPs. The research found that inserting VP4 into the spike induced VP4-specific antibodies, while attaching VP4 peptides to the spikes did not.
Article
Microbiology
Alexandra Hardy, Siddharth Bakshi, Wilhelm Furnon, Oscar MacLean, Quan Gu, Margus Varjak, Mariana Varela, Muhamad Afiq Aziz, Andrew E. E. Shaw, Rute Maria Pinto, Natalia Cameron Ruiz, Catrina Mullan, Aislynn E. E. Taggart, Ana Da Silva Filipe, Richard E. E. Randall, Sam J. J. Wilson, Meredith E. E. Stewart, Massimo Palmarini
Summary: Infected hosts have two strategies to protect themselves: resistance and disease tolerance. In this study, the mechanisms of virus-host interactions related to disease tolerance were investigated using bluetongue virus (BTV) as a model. The replication of BTV was higher in sheep cells than in cattle cells, and this difference was abolished by suppressing the cell's type I interferon response. Furthermore, BTV induced a faster shutdown of host cell protein synthesis in sheep cells, leading to downregulation of antiviral proteins.
Article
Immunology
Elizabeth B. Brickley, Ruth Connor, Wendy Wieland-Alter, Joshua A. Weiner, Margaret E. Ackerman, Minetaro Arita, Chris Gast, Ilse De Coster, Pierre Van Damme, Ananda S. Bandyopadhyay, Peter F. Wright
Summary: In a phase 1 trial, two novel type 2 oral poliovirus vaccine candidates induced detectable poliovirus type 2-specific intestinal neutralizing responses in 40.0% and 46.7% of participants, respectively, suggesting potential utility for reducing circulating vaccine-derived poliovirus transmission under outbreak scenarios.
JOURNAL OF INFECTIOUS DISEASES
(2022)
Article
Biochemistry & Molecular Biology
Xiaomin Guo, Pengcheng Ma, Yuwei Li, Yanan Yang, Chaoming Wang, Tao Xu, Huishan Wang, Chaocui Li, Bingyu Mao, Xiaopeng Qi
Summary: The study demonstrated that ubiquitination of STAT1 by the E3 ligase RNF220 plays a significant role in STAT1 activation and innate immune responses. Deficiency in Rnf220 gene leads to downregulation of IFN signaling and decreased expression of ISGs, making RNF220 a potential therapeutic target against bacterial and viral infection and inflammatory diseases.
CELL DEATH AND DIFFERENTIATION
(2021)
Review
Immunology
Zahra Yousefi, Hamid Aria, Farhoodeh Ghaedrahmati, Tahereh Bakhtiari, Mahdieh Azizi, Reza Bastan, Reza Hosseini, Nahid Eskandari
Summary: This review provides a comprehensive overview of HPV vaccines, discussing their types and efficacy. Prophylactic vaccines, which are highly immunogenic and induce neutralizing antibodies, have been approved for targeting high-risk HPV types. Therapeutic vaccines, on the other hand, aim to stimulate cell-mediated immunity against transformed cells. The second generation of prophylactic vaccines, using alternative viral components and cost-effective production strategies, is currently under clinical evaluation.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Carlos U. Torres-Estrella, Maria del Rocio Reyes-Montes, Esperanza Duarte-Escalante, Monica Sierra Martinez, Maria Guadalupe Frias-De-Leon, Gustavo Acosta-Altamirano
Summary: This paper describes the current status of COVID-19 vaccine development and production, and proposes ideas for future research. The paper also discusses the immune effects of vaccination in different populations and the role of Mexico in managing the vaccination process.
Article
Oncology
Dimitrios Nasioudis, Stefan Gysler, Nawar Latif, Lory Cory, Robert L. Giuntoli II, Sarah H. Kim, Fiona Simpkins, Lainie Martin, Emily M. Ko
Summary: The prevalence of ERBB2 gene amplification was investigated among patients with gynecologic malignancies. The study found that ERBB2 amplification is frequently encountered in uterine serous carcinoma and mucinous ovarian carcinoma, but less common in endometrioid endometrial carcinoma.
GYNECOLOGIC ONCOLOGY
(2024)